Current advances in using tolerogenic dendritic cells as a therapeutic alternative in the treatment of type 1 diabetes.
Ontology highlight
ABSTRACT: Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of insulin-producing β-cells of the pancreatic islets by autoreactive T cells, leading to high blood glucose levels and severe long-term complications. The typical treatment indicated in T1D is exogenous insulin administration, which controls glucose levels; however, it does not stop the autoimmune process. Various strategies have been implemented aimed at stopping β-cell destruction, such as cellular therapy. Dendritic cells (DCs) as an alternative in cellular therapy have gained great interest for autoimmune disease therapy due to their plasticity to acquire immunoregulatory properties both in vivo and in vitro, performing functions such as anti-inflammatory cytokine secretion and suppression of
SUBMITTER: Rios-Rios WJ
PROVIDER: S-EPMC8107985 | biostudies-literature | 2021 May
REPOSITORIES: biostudies-literature
ACCESS DATA